ASX Biotech Stocks Working on Cancer, Ranked by Size, Stage and Cash
Samso counted 26 ASX biotech stocks working on treating or finding cancer, and the largest, Telix, is worth more than twice the other ranked companies combined. Most are micro caps, and many are still in early trials. Ten had less than two quarters of cash at 30 September 2026, and most of those have topped up since. For many of the smaller ones, the next trial result and the next capital raising are likely to come close together.



